Last reviewed · How we verify

Skelid — Competitive Intelligence Brief

Skelid (TILUDRONIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate. Area: Bone.

marketed Bisphosphonate 72 kDa type IV collagenase Bone Small molecule Live · refreshed every 30 min

Target snapshot

Skelid (TILUDRONIC ACID).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Skelid TARGET TILUDRONIC ACID marketed Bisphosphonate 72 kDa type IV collagenase 1997-01-01
Liposomal Doxorubicin liposomal-doxorubicin Pfizer marketed doxorubicin 72 kDa type IV collagenase 1974-01-01
Vibramycin doxycycline Generic (originally Pfizer) marketed Tetracycline antibiotic 72 kDa type IV collagenase, Stromelysin-1, Collagenase 3 1967-01-01
Chlorhexidin Chlorhexidin Krishnadevaraya College of Dental Sciences & Hospital marketed Synaptojanin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9
Zoledronate Zoledronate Children's Hospital Medical Center, Cincinnati marketed Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase
Doxycyclin Doxycyclin Bulovka Hospital marketed 72 kDa type IV collagenase, Stromelysin-1, Collagenase 3
Zometa Zometa University of Arkansas marketed Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Bisphosphonate class)

  1. · 2 drugs in this class
  2. Amgen · 2 drugs in this class
  3. National Taiwan University Hospital · 2 drugs in this class
  4. Sanofi · 2 drugs in this class
  5. Ludwig-Maximilians - University of Munich · 2 drugs in this class
  6. Chinese University of Hong Kong · 1 drug in this class
  7. Chinese Society of Lung Cancer · 1 drug in this class
  8. Aarhus University Hospital · 1 drug in this class
  9. Eisai Inc. · 1 drug in this class
  10. Daiichi Sankyo Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Skelid — Competitive Intelligence Brief. https://druglandscape.com/ci/tiludronic-acid. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: